SOURCE-LINKED STUDY SUMMARY
Tirzepatide and oral progestogens: A hypothesis-generating review of a biologically plausible pharmacokinetic interaction in gynaecologic disease control and menopausal hormone therapy.
Abstract summarizedQuality not appraised
- What was studied
- A narrative review examined whether tirzepatide changes absorption of oral progestogens used for gynaecologic conditions or menopausal hormone therapy.
- Who / model studied
- The review searched literature through February 2026 and found one pharmacokinetic study using a combined oral contraceptive. Its participant count is not stated in the abstract.
- Studied dose & schedule
- Dose and schedule have not yet been extracted for this summary.
- What the study found
- In that single-dose study, peak hormone concentrations fell 55–66%, total exposure fell 20–23%, and peaks occurred 2.5–4.5 hours later.
- Limitations & context
- Lower peak concentrations do not establish reduced effectiveness. Equivalent data for therapeutic or menopausal progestogens were absent, and clinical effects remain untested.
Read summary source ↗ · Prepared 9/15/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1016/j.maturitas.2026.109116